Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has raised A$4 million to support commercial licensing activity, clinical ...
Cefadroxil (Recef DT (250mg)) is broad-spectrum antibiotic, prescribed for certain types of bacterial infections such as urinary tract infection, skin and soft- tissue, pharynx (throat) and tonsils ...
Find the latest Recce Pharmaceuticals Ltd (RECEF) stock quote, history, news and other vital information to help you with your stock trading and investing.
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
At close: 29 June at 4:00:00 pm GMT-4 ...
At close: 4 February at 4:00:00 pm GMT-5 ...
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) ...
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...
Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data analysis expected in Q1 2025Additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results